Press briefing 2 Breast cancer
Moderator and Commentator LBA8_PR: Giuseppe Curigliano, Italy
Commentator LBA6_PR and LBA7_PR: Nadia Harbeck, Germany
Link to press releases and abstracts
- LBA6_PR - MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer see also: JAMA: Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Breast Cancer That Progressed on Endocrine Therapy
George Sledge, US - LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Dennis Slamon, US - LBA8_PR - KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) Peter Schmid, UK